Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
about
New modalities of cancer treatment for NSCLC: focus on immunotherapyThe effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.Decreased HCRP1 expression is associated with poor prognosis in breast cancer patientsConcomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung CancersPrimary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases.EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysisPotential biomarkers in psychiatry: focus on the cholesterol system.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Targeting PI3K in Cancer: Any Good News?The potential of biomarkers in psychiatry: focus on proteomics.miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).Rap2b promotes proliferation, migration, and invasion of lung cancer cells.
P2860
Q26829161-5A51DE84-2EE1-434A-956F-70961FA6C036Q33632386-28606EE0-C255-4D4F-9DEA-964C967F55D2Q34732984-A70489C8-3EA8-436F-94AB-6AA050D76849Q36418752-9701E84E-8B81-4B08-B42A-CB55DD588D22Q36478397-E012AE44-C123-458B-9D80-5A88DEED4B1BQ36619212-234C4D8F-1E9B-44E4-963F-14555C37BBFDQ37645248-3C8B4B58-7448-463C-9ECF-9CFFA2AA0819Q37981261-2A89D205-8AF1-4CCE-8195-1F34C6C7D057Q38042638-B75864AA-E47F-4160-91F0-43EA3145C4D1Q38105322-11C2E073-723C-4516-8DE4-39B3FF95382BQ38172847-B1B5A69B-ED32-4280-942E-03585C94CD30Q38911621-1458CA79-3241-44F0-8538-C415D071CFB8Q43441821-18D479B3-3BB6-45F5-A7FB-13F96F223E3FQ51564853-8D0C0165-0428-4186-B9DD-77D6D1D29877
P2860
Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@ast
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@en
type
label
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@ast
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@en
prefLabel
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@ast
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@en
P2093
P2860
P921
P356
P1476
Biomarkers of clinical benefit ...... ith non-small-cell lung cancer
@en
P2093
A G Pallis
D A Fennell
E Szutowicz
L Greillier
N B Leighl
P2860
P2888
P356
10.1038/BJC.2011.207
P407
P577
2011-06-07T00:00:00Z